Total revenue of $230.2 million grew 25% year-over-year and annual revenue exceeded previously-established outlook Net loss and Adjusted EBITDA1 improved to ($32.5) million and $4.4 million, respectively GPV as a percentage of GTV was 32% in the quarter, up from 19% in the prior year ARPU2 of ~$431 grew 29% year-over-year with Net Retention Rate of ~110% Lightspeed reports in US dollars and in accordance with IFRS.

SMITHS FALLS, ON, May 16, 2024 /CNW/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX: WEED) (NASDAQ: CGC), a world-leading cannabis company dedicated to unleashing the power of cannabis, will release its financial results for the fourth quarter and fiscal year 2024 ended March 31, 2024 before financial markets open on May 30, 2024.

Company continues to advance its corticosteroid production platform and anticipates signing a large strategic partnership in Q2 2024 Signed two new program agreements, and advanced three programs to the next phase of development toward commercialization Willow reiterates its expectations of at least doubling its full year 2024 revenues SUNNYVALE, Calif., May 13, 2024 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable functional ingredients, today released its financial and operating results for the three months ended March 31, 2024, reporting significantly reduced costs and further ...

Newly created directorship to be filled by Rajesh Uttamchandani EDMONTON, AB, May 15, 2024 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian based leading global medical cannabis company, announced today the appointment of Rajesh Uttamchandani to the Company's Board of Directors (the "Board"), effective today.